18
Participants
Start Date
May 11, 2021
Primary Completion Date
April 14, 2022
Study Completion Date
August 9, 2022
PF-06946860
subcutaneous injection
Placebo for PF-06946860
subcutaneous injection
Cancer Center IDS Pharmacy, Charlottesville
University of Virginia Cancer Center, Charlottesville
UVA Health System; Attention: GI Team, Charlottesville
University of Virginia Health System, Charlottesville
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
Bozeman Health Cancer Center, Bozeman
Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research, Bozeman
Bozeman Health Deaconess Hospital, Bozeman
CARTI Cancer Center, Little Rock
US Oncology Investigational Product Center (IPC), Irving
Mary Crowley Cancer Research, Dallas
Texas Oncology-Paris, Paris
Texas Oncology - Longview Cancer Center, Longview
Texas Oncology- Tyler, Tyler
The University of Texas MD Anderson Cancer Center, Houston
Lutheran Medical Center, Wheat Ridge
Cedars- Sinai Medical Center, Los Angeles
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
Tower Hematology Oncology Medical Group (THO), Beverly Hills
Ventura County Hematology-Oncology Specialists, Ventura
Ventura County Hematology- Oncology Specialists, Camarillo
Ventura County Hematology Oncology Specialists, Oxnard
Providence Medical Foundation, Santa Rosa
MultiCare Regional Cancer Center - Auburn, Auburn
MultiCare Regional Cancer Center - Gig Harbor Medical Park, Gig Harbor
MultiCare Regional Cancer Center - Puyallup, Puyallup
MultiCare Institute for Research & Innovation, Tacoma
MultiCare Regional Cancer Center - Tacoma, Tacoma
Wenatchee Valley Hospital, Wenatchee
Moses Lake Clinic, Moses Lake
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane Valley
The Ottawa Hospital Cancer Centre, Ottawa
Lead Sponsor
Pfizer
INDUSTRY